NR3C2 and myocardial infarction: Mineralocorticoid receptor antagonists (MRAs) are a fundamentally important therapy for patients with heart failure (HF) and reduced ejection fraction (HFrEF),1, 2 and selected patients with left ventricular dysfunction after myocardial infarction (MI).3